文献速递支持与姑息治疗

抗癌药物超常反应者生物医学文献综合综述

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature.
PubMed 文献 · Eur J Cancer · 2018-07-27

该系统综述检索生物医学文献并手工检索七本肿瘤学期刊,纳入180例转移或不可切除癌症成人患者对药物治疗出现显著反应的病例报告。最常见为乳腺癌和靶向治疗,中位反应持续时间14个月,但许多病例缺失反应关键信息,建议未来使用标准化标准。

要点

  • 超常反应者多为实体瘤且接受靶向治疗。
  • 许多病例报告缺失反应持续时间和关键肿瘤病史。
  • 建议采用标准化标准以提高病例报告可用性。

核心结论

  • 超常反应者倾向于实体器官恶性肿瘤,且大多数接受靶向治疗。
  • 许多超常反应病例缺失关于反应和关键肿瘤病史的重要信息。
  • 未来应使用标准化标准以最大化这些病例报告的实用性。

研究设计与样本

  • 系统检索生物医学文献并手工检索七本著名肿瘤学期刊。
  • 纳入成人转移或不可切除癌症患者,经分类为对药物治疗有显著反应。
  • 研究于2017年1月至2017年4月进行。

主要发现

  • 共发现180例超常反应病例。
  • 最常见恶性肿瘤为乳腺癌(28/180)。
  • 最常见药物类别为靶向治疗(161/274)。
  • 中位发表年份为2015年。
  • 反应深度包括33%(61/180)完全缓解、55%(100/180)部分缓解和7.7%(14/180)疾病稳定。

关键数值与推荐

  • 中位反应持续时间为14个月。
  • 仅14%(26/180)报告了观察到此反应的分母或治疗总人数。
  • 在报告不可切除设置下既往药物反应持续时间的病例中,49%显示超常反应对先前治疗线的无进展生存比(Von Hoff比)≥1.3。

临床怎么用

  • 临床医生应关注超常反应病例,但需注意文献中信息缺失常见。
  • 未来病例报告应遵循标准化标准,完整记录反应持续时间和相关研究。

局限性

  • 仅基于已发表病例报告,可能存在发表偏倚。
  • 许多病例缺失反应持续时间和关键肿瘤病史信息。
  • 仅手工检索七本肿瘤学期刊,可能遗漏其他来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is broad interest in patients who have exceptional responses to cancer drugs and only one prior systematic review of published case reports. OBJECTIVE: To systematically summarise case reports of patients who have had a super response to a cancer drug and determine patterns and completeness of documentation. DESIGN, SETTING AND PARTICIPANTS: This is a systematic search of biomedical literature and hand searches of seven prominent oncology journals. All cases were adults with cancer in the metastatic or unresectable setting and who were classified as having a remarkable response to a drug therapy were included. Our study was conducted between January 2017 and April 2017. MAIN OUTCOMES AND MEASURES: We extracted patient and tumour characteristics, characteristics surrounding the exceptional response and pertinent oncologic history. Additionally, we noted authors' financial conflicts of interest, if given. RESULTS: We found 180 cases of exceptional response. The most common malignancy was breast cancer (28/180), and the most common class of drug therapy used was targeted therapies (161/274). The median year of publication was 2015. Depth of response included 33% (61/180) complete response, 55% (100/180) partial response and 7.7% (14/180) stable disease. The median length of response to the drug was 14 months. Fifty-nine percent (107/180) reported a driver mutation, and only 52% (56/107) reported two or more correlative studies. Only 14% (26/180) reported a denominator or total number treated to observe this response. Of cases that reported duration of response to a previous drug given in the unresectable setting, 49% demonstrated a progression-free survival ratio of exceptional response to prior line of 1.3 or greater (Von Hoff ratio). CONCLUSIONS AND RELEVANCE: Our survey found that exceptional responders tended to have solid organ malignancies and most received targeted therapies. Many of our cases of exceptional responders were missing important information about the response and key oncologic history. Standardised criteria should be used to maximise usefulness of these case reports in the future.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nishikawa G, Luo J, Prasad V, et al. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018. PMID: 30059818. doi:10.1016/j.ejca.2018.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。